Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
CYTK · Why this verdict
Why Cytokinetics (CYTK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A risk/reward of approximately 4.6-to-1 and 32% upside to analyst consensus reflects high commercial expectations for a single cardiac product, offset by deeply negative free cash flow running at more than three times revenue, 18% short interest, and business quality below the minimum acceptable threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
With the stock roughly 32% below analyst consensus and a risk/reward ratio of approximately 4.6-to-1 in favor of the bull case, the asymmetric setup offers meaningful potential return relative to the defined downside. Price targets | The stock closes at least half the gap to analyst consensus within 12 months, implying a move to approximately $82. | →Stable |
| CounterA 32% discount to consensus on a pre-profitability biotech often reflects market skepticism about commercial execution rather than a pricing error; if the lead product disappoints, consensus targets will be revised down toward the current price, closing the gap from the wrong direction. | ||
Free cash flow is deeply negative, with cash outflows running at more than three times annual revenue — a pace that requires continuous external financing and creates ongoing dilution risk for equity holders. Quality breakdown | If the thesis holds and commercial revenue ramps, free cash flow losses narrow to less than 100% of revenue within four quarters. | →Stable |
| CounterAt the current burn rate, each quarter adds to dilution pressure and financing dependency; if capital markets tighten or the commercial launch disappoints, the burn could prove unsustainable before the business reaches self-funding. | ||
Revenue is concentrated almost entirely in a single cardiac product (MYQORZO) with sole-source contract manufacturers, making the investment outcome binary — one asset's commercial trajectory drives nearly all enterprise value. Bear case | The lead product generates positive sequential revenue growth for at least three of the next four reported quarters, demonstrating that the concentration risk is being resolved through uptake. | →Stable |
| CounterA single-product dependency compounded by sole-source manufacturing means any label restriction, reimbursement setback, or supply disruption could simultaneously impair revenue and supply chain, with no other product line to buffer the impact. | ||
Short interest of 18% of the float represents a substantial overhang that can amplify downside volatility if near-term catalysts disappoint, as short sellers have built large positions against the commercial story. Risk breakdown | Short interest falls below 12% of the float within six months as commercial traction reduces conviction among short sellers. | →Stable |
| CounterConcentrated short positioning also creates conditions for a sharp squeeze on positive data, potentially accelerating any upside move well beyond the consensus target. | ||
With the stock roughly 32% below analyst consensus and a risk/reward ratio of approximately 4.6-to-1 in favor of the bull case, the asymmetric setup offers meaningful potential return relative to the defined downside.
→StablePrice targets
- Expectation
- The stock closes at least half the gap to analyst consensus within 12 months, implying a move to approximately $82.
CounterA 32% discount to consensus on a pre-profitability biotech often reflects market skepticism about commercial execution rather than a pricing error; if the lead product disappoints, consensus targets will be revised down toward the current price, closing the gap from the wrong direction.
Free cash flow is deeply negative, with cash outflows running at more than three times annual revenue — a pace that requires continuous external financing and creates ongoing dilution risk for equity holders.
→StableQuality breakdown
- Expectation
- If the thesis holds and commercial revenue ramps, free cash flow losses narrow to less than 100% of revenue within four quarters.
CounterAt the current burn rate, each quarter adds to dilution pressure and financing dependency; if capital markets tighten or the commercial launch disappoints, the burn could prove unsustainable before the business reaches self-funding.
Revenue is concentrated almost entirely in a single cardiac product (MYQORZO) with sole-source contract manufacturers, making the investment outcome binary — one asset's commercial trajectory drives nearly all enterprise value.
→StableBear case
- Expectation
- The lead product generates positive sequential revenue growth for at least three of the next four reported quarters, demonstrating that the concentration risk is being resolved through uptake.
CounterA single-product dependency compounded by sole-source manufacturing means any label restriction, reimbursement setback, or supply disruption could simultaneously impair revenue and supply chain, with no other product line to buffer the impact.
Short interest of 18% of the float represents a substantial overhang that can amplify downside volatility if near-term catalysts disappoint, as short sellers have built large positions against the commercial story.
→StableRisk breakdown
- Expectation
- Short interest falls below 12% of the float within six months as commercial traction reduces conviction among short sellers.
CounterConcentrated short positioning also creates conditions for a sharp squeeze on positive data, potentially accelerating any upside move well beyond the consensus target.
Per-dimension breakdown
Quality
3.1/10data confidence 86%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.8 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -360% of revenue
Growth
5.0/10data confidence 50%Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 73)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.8 |
| Analyst rating | 7.5 |
| Price target | 8.4 |
- ▸LLM news sentiment: +0.55 (n=1)
- ▸Analyst upside: 28%
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $13,651,598 (0.124% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.3 |
| 52w position | 9.9 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.7 |
| days to cover | 6.2 |
| volatility | 2.4 |
| put call | 8.7 |
| implied vol | 4.9 |
| max pain risk | 3.0 |
| beta | 10.0 |
- ▸High short interest justified: 18%
- ▸Above max pain $55
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 3.6 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.7>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:42d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.0<1.5@spot
Warning (0)
none
Reward-to-Risk
1.02
Upside
+15.3%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.9 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.0<1.5@spot.
The strongest dimensions are Sentiment at 7.9, Value at 7.5, and Momentum at 6.7; the weakest are Quality at 3.1, Insider at 3.3, and Technical at 3.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.02 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1With the stock roughly 32% below analyst consensus and a risk/reward ratio of approximately 4.6-to-1 in favor of the bull case, the asymmetric setup offers meaningful potential return relative to the defined downside.
Trip ifAnalyst consensus price target falls below $75, cutting implied upside to less than 5% from the current price.
- P2Free cash flow is deeply negative, with cash outflows running at more than three times annual revenue — a pace that requires continuous external financing and creates ongoing dilution risk for equity holders.
Trip ifFree cash flow loss narrows to less than 100% of revenue for 2 consecutive quarters, indicating the burn rate is on a path toward sustainability.
- P3Revenue is concentrated almost entirely in a single cardiac product (MYQORZO) with sole-source contract manufacturers, making the investment outcome binary — one asset's commercial trajectory drives nearly all enterprise value.
Trip ifMYQORZO sequential quarterly revenue growth falls below 0% for 2 consecutive quarters, indicating the single product's commercial trajectory has reversed.
- P4Short interest of 18% of the float represents a substantial overhang that can amplify downside volatility if near-term catalysts disappoint, as short sellers have built large positions against the commercial story.
Trip ifShort interest falls below 10% of the float for 2 consecutive months, indicating short sellers have substantially covered.